JP7820294B2 - 脂肪性肝疾患の治療用医薬 - Google Patents

脂肪性肝疾患の治療用医薬

Info

Publication number
JP7820294B2
JP7820294B2 JP2022524526A JP2022524526A JP7820294B2 JP 7820294 B2 JP7820294 B2 JP 7820294B2 JP 2022524526 A JP2022524526 A JP 2022524526A JP 2022524526 A JP2022524526 A JP 2022524526A JP 7820294 B2 JP7820294 B2 JP 7820294B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
fatty liver
liver disease
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524526A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021235508A5 (https=
JPWO2021235508A1 (https=
Inventor
日出男 雪岡
淳行 島崎
忠輝 濱田
巨樹 大藪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2021235508A1 publication Critical patent/JPWO2021235508A1/ja
Publication of JPWO2021235508A5 publication Critical patent/JPWO2021235508A5/ja
Application granted granted Critical
Publication of JP7820294B2 publication Critical patent/JP7820294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022524526A 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬 Active JP7820294B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020089196 2020-05-21
JP2020089196 2020-05-21
JP2020134338 2020-08-07
JP2020134338 2020-08-07
PCT/JP2021/019088 WO2021235508A1 (ja) 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬

Publications (3)

Publication Number Publication Date
JPWO2021235508A1 JPWO2021235508A1 (https=) 2021-11-25
JPWO2021235508A5 JPWO2021235508A5 (https=) 2024-05-27
JP7820294B2 true JP7820294B2 (ja) 2026-02-25

Family

ID=78707930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524526A Active JP7820294B2 (ja) 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬

Country Status (10)

Country Link
US (2) US12521375B2 (https=)
EP (1) EP4154880A4 (https=)
JP (1) JP7820294B2 (https=)
KR (1) KR20230013126A (https=)
CN (1) CN115666558A (https=)
AU (1) AU2021275292A1 (https=)
CA (1) CA3182134A1 (https=)
MX (1) MX2022014553A (https=)
TW (1) TW202207919A (https=)
WO (1) WO2021235508A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023090411A1 (https=) 2021-11-19 2023-05-25

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523225A (ja) 2000-12-26 2004-08-05 リサーチ　ディベロップメント　ファンデーション 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２
JP2013542218A (ja) 2010-10-29 2013-11-21 ファイザー・インク Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤
WO2016159082A1 (ja) 2015-03-30 2016-10-06 塩野義製薬株式会社 ９員縮合環誘導体
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
WO2019006324A1 (en) 2017-06-30 2019-01-03 Quixgen, Inc. NEW SPIROLACTONE COMPOUNDS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548738B2 (en) 2000-12-26 2003-04-15 Research Development Foundation ACC2-knockout mice and uses thereof
WO2009144555A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2947082A1 (en) 2009-11-10 2015-11-25 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
JP6205152B2 (ja) 2013-03-25 2017-09-27 サイプレス セミコンダクター コーポレーション シリアル通信システム、受信装置およびシリアル通信方法
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
CN109072302B (zh) * 2016-03-30 2024-01-16 基恩菲特公司 非酒精性脂肪性肝炎的非侵入性诊断

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523225A (ja) 2000-12-26 2004-08-05 リサーチ　ディベロップメント　ファンデーション 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２
JP2013542218A (ja) 2010-10-29 2013-11-21 ファイザー・インク Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
WO2016159082A1 (ja) 2015-03-30 2016-10-06 塩野義製薬株式会社 ９員縮合環誘導体
WO2019006324A1 (en) 2017-06-30 2019-01-03 Quixgen, Inc. NEW SPIROLACTONE COMPOUNDS

Also Published As

Publication number Publication date
CN115666558A (zh) 2023-01-31
WO2021235508A1 (ja) 2021-11-25
MX2022014553A (es) 2022-12-15
US20260091022A1 (en) 2026-04-02
EP4154880A4 (en) 2024-06-05
KR20230013126A (ko) 2023-01-26
EP4154880A1 (en) 2023-03-29
AU2021275292A1 (en) 2022-12-15
TW202207919A (zh) 2022-03-01
CA3182134A1 (en) 2021-11-25
JPWO2021235508A1 (https=) 2021-11-25
US20230210822A1 (en) 2023-07-06
US12521375B2 (en) 2026-01-13

Similar Documents

Publication Publication Date Title
JP7060298B1 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
CN106117193A (zh) 新的杂环衍生物及其在神经性疾病治疗中的应用
RU2720488C2 (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
JP7150032B2 (ja) グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
WO2020007322A1 (zh) 一种靶向降解bet蛋白的化合物及其应用
JP7068743B2 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
US20260098031A1 (en) Monocyclic compound having glp-1 receptor agonist activity
US20260091022A1 (en) Pharmaceutical composition for treating fatty liver disease
KR20230135040A (ko) 트랜스티레틴 사량체를 안정화하는 레티놀-결합 단백질 4의 이중특이성 길항제, 이들의 제조 및 일반적인 연령-관련 동반질환의 치료에서의 용도
EP4370519A1 (en) 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
BR112021012428A2 (pt) Derivado de dihidropirazolopirazinona tendo atividade inibitória de mgat2
US20250041279A1 (en) Therapeutic medicine for heart disease or skeletal muscle disease
WO2017110841A1 (ja) Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
HK40082231A (en) Pharmaceutical for treating fatty liver diseases
WO2024182742A1 (en) Nbd1 modulators and methods of using the same
EP4673138A1 (en) Nbd1 modulators and methods of using the same
CN118715220A (zh) 2-((4-((s)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((s)-氧杂环丁烷-2-基)甲基)-1h-咪唑衍生物作为glp1受体激活剂用于治疗肥胖症
BR112020006456A2 (pt) compostos químicos

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231019

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260212

R150 Certificate of patent or registration of utility model

Ref document number: 7820294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150